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Abstract
AIM: To compare the efficacy and safety of sedation 
protocols for endoscopic submucosal dissection (ESD) 
between dexmedetomidine-remifentanil and propofol-
remifentanil.
METHODS: Fifty-nine patients scheduled for ESD 
were randomly allocated into a dexmedetomidine-
remifentanil (DR) group or a propofol-remifentanil (PR) 
group. To control patient anxiety, dexmedetomidine or 
propofol was infused to maintain a score of 4-5 on the 
Modified Observer’s Assessment of Alertness/Sedation 
scale. Remifentanil was infused continuously at a 
rate of 6 μg/kg per hour in both groups. The ease of 
advancing the scope into the throat, gastric motility 
grading, and satisfaction of the endoscopist and patient 
were assessed. Hemodynamic variables and hypoxemic 
events were compared to evaluate patient safety.
RESULTS: Demographic data were comparable 
between the groups. The hemodynamic variables and 
pulse oximetry values were stable during the procedure 
in both groups despite a lower heart rate in the DR 
group. No oxygen desaturation events occurred in 
either group. Although advancing the scope into the 
throat was easier in the PR group (“very easy” 24.1% 
vs  56.7%, P  = 0.010), gastric motility was more 
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suppressed in the DR group (“no + mild” 96.6% vs  
73.3%, P  = 0.013). The endoscopists felt that the 
procedure was more favorable in the DR group (“very 
good + good” 100% vs  86.7%, P  = 0.042), whereas 
patient satisfaction scores were comparable between 
the groups. En bloc  resection was performed 100% of 
the time in both groups, and the complete resection 
rate was 94.4% in the DR group and 100% in the PR 
group (P  = 0.477). 
CONCLUSION: The efficacy and safety of dexme-
detomidine and remifentanil were comparable to 
propofol and remifentanil during ESD. However, the 
endoscopists favored dexmedetomidine perhaps due to 
lower gastric motility. 
Key words: Dexmedetomidine; Efficacy; Peristalsis; 
Safety; Endoscopic submucosal dissection
© The Author(s) 2015. Published by Baishideng Publishing 
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Core tip: Propofol and remifentanil are effectively used 
for endoscopic procedures. However, deep sedation 
especially with propofol is frequently associated with 
cardiorespiratory complications; therefore, it is of 
interest to identify shallower yet equally effective 
sedation protocols. Dexmedetomidine allows sedation 
without respiratory depression, and has also been 
utilized for sedation for endoscopic procedures. This 
study compared the efficacy and safety between 
propofol-remifentanil and dexmedetomidine-remi-
fentanil during endoscopic submucosal dissection 
(ESD) from the perspective of the endoscopist and 
the patient. We found that efficacy and safety of 
dexmedetomidine-remifentanil were comparable to 
propofol-remifentanil during ESD, but the endoscopists 
favored the dexmedetomidine-remifentanil regimen 
perhaps due to lower gastric motility.
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INTRODUCTION
Endoscopic submucosal dissection (ESD) is associated 
with greater and longer patient discomfort and pain 
than other endoscopic procedures. Therefore, it is 
of interest to reduce pain and discomfort associated 
with ESD[1]. Propofol has been widely used for endo­
scopic procedures[2,3]. It is safe and effective[4] and 
is associated with shorter recovery time and better 
sedation and amnesia levels without an increased 
risk for cardiopulmonary complications[5] than other 
traditional sedatives. However, in addition to the 
dose­dependent respiratory depression of propofol, 
aspiration pneumonia occurs with an incidence of 
2.3% following ESD[6]. Moreover, it is difficult to control 
sedation depth with propofol[7]. However, its use in 
combination with other analgesics can offset these 
complications by reducing the dose of propofol[8].
Dexmedetomidine, a selective α2­adrenoceptor 
agonist with sedative and analgesic effects, has been 
successfully used during colonoscopy[9], cystoscopy[10] 
and ESD[11]. Dexmedetomidine suppresses gastro­
intestinal motility and inhibits gastric emptying in 
healthy volunteers[12] whereas propofol does not[13]. 
Suppressing gastric motility may be crucial for succe­
ssful ESD. 
In this study, we compared the procedural efficacy 
and patient safety of the use of dexmedetomidine­
remifentanil vs propofol­remifentanil during ESD. 
MATERIALS AND METHODS
Patient and sedation protocol
This study was approved by the Institutional Review 
Board of Severance Hospital, Yonsei University Health 
System (ref: 4­2012­0621) and was registered at 
http://ClinicalTrials.gov (ref: NCT01920113). Written 
informed consent was obtained from all patients 
before the procedure. Sixty patients aged > 20 years 
belonging to American Society of Anesthesiologists 
classification Ⅰ­Ⅲ and scheduled for ESD were enrolled 
in this prospective, randomized, and endoscopist­blind 
study from September 2012 to January 2013. Patients 
with end­organ diseases (i.e., heart failure, respiratory 
failure, hepatic failure, or renal failure), known drug 
allergies, or a history of drug abuse were excluded. 
The patients were randomly assigned to the 
dexmedetomidine­remifentanil group (DR group, n 
= 30) or the propofol­remifentanil group (PR group, 
n = 30) using a random number table provided by 
www.random.org. Among the 60 patients, data for 59 
patients (29 patients in the DR group and 30 patients 
in the PR group) were analysed; surgical removal was 
considered in one patient.
Both the endoscopists and patients were blinded to 
the sedation protocol. None of the patients were pre­
medicated. The level of sedation in both groups was 
targeted to a score of 4-5 on the Modified Observer’
s Assessment of Alertness/Sedation scale[14] (MOAA/
S, Table 1) for minimal sedation during the entire 
procedure. For the DR group, a bolus dose of 0.5 μg/
kg dexmedetomidine (Precedex®, Abbott, Istanbul, 
Turkey) was injected intravenously for 5 min before 
starting the procedure. Thereafter, a continuous 
infusion dose of 0.3­0.7 μg/kg per hour was given. 
For the PR group, a bolus injection of 0.5 mg/kg 
propofol was followed by continuous infusion at a rate 
of 30 μg/kg per minute (Pofol®, Dongkook Pharm. 
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Co. Ltd., Seoul, South Korea) using an infusion pump 
(Syringe Pump TE­331, Terumo, Tokyo, Japan). In 
both groups, remifentanil (Ultiva®, GlaxoSmithKline, 
Co. Ltd., Genval, Belgium) was infused continuously 
at the rate of 6 μg/kg per hour beginning 5 min before 
commencing the procedure. 
We monitored the MOAA/S scale score continuously. 
If the score was 6 or the patient wanted deeper 
sedation, a bolus of 10 mg propofol was administered. 
If the patient complained of pain during the procedure, 
0.1 μg/kg remifentanil bolus was administered, and its 
infusion rate was increased by 0.1 μg/kg per hour.  
Hartman’s solution was administered at a rate of 
3­5 mL/kg per hour, and 2 L/min oxygen was given 
through a nasal cannula. Oxygen saturation (SpO2), 
systolic and diastolic blood pressure (SBP and DBP), 
electrocardiogram (ECG), and heart rate (HR) were 
monitored continuously and recorded at 5­min 
intervals.
The MOAA/S scale score was recorded as follows: 
just before the procedure (baseline, T0); 1 min after 
induction of sedation (1 min after a 5 min loading of 
dexmedetomidine in the DR group and 1 min after 
the propofol bolus injection in the PR group, T1); as 
the endoscope was passed into the esophagus (T2); 
as the tumor margin was marked by argon plasma 
coagulation (T3); 5 min after an injection of normal 
saline containing epinephrine (0.01 mg/mL) was given 
in the gastric submucosa (T4); at dissection of the 
gastric tumor region from the gastric submucosa (T5); 
once bleeding control was performed at the gastric bed 
after dissection (T6); and at the end of the procedure 
(T7). 
The discharge Aldrete score[15] (Table 2) was 
recorded to document the patient’s general status at 
the end of the procedure. 
All patients were observed in the post­anesthetic 
care unit (PACU) until their discharge Aldrete score 
reached 10. 
Assessment of the efficacy of procedural performance
The ease of advancing the scope through the throat 
(four grades: very easy, easy, slight difficulty, and 
difficult), gastric motility[16] (four grades: no, mild, 
moderate, and vigorous) (Table 3), and procedural 
satisfaction (four grades: very good, good, fair, and 
bad) were evaluated by the endoscopists. Gastric 
motility was assessed at the time after the scope had 
reached to stomach. Thereafter butylscopolamine 
(20 mg) was administered to suppress gastric 
motility during the procedure at the request of the 
endoscopists. The total amount of butylscopolamine 
used was recorded.
The rate of en bloc resection and complete 
resection (defined as en bloc resection with tumor­free 
margins)[17] was compared between the groups.
Patients were also asked about their satisfaction 
with the procedure (four grades: very good, good, 
bearable, and unbearable) before discharge from the 
PACU. 
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Table 1  Modified observer’s assessment of alertness/sedation
Alertness/
sedation level
Description
6 Agitated
5 Respond readily to name spoken in normal tone (alert)
4 Lethargic response to name spoken in normal tone
3 Responds only after name is called loudly, repeatedly, or 
both
2 Responds only after mild prodding or shaking
1 Does not respond to mild prodding or shaking
0 Does not respond to deep stimulus (asleep)
Table 3  Evaluation of gastric motility
Table 2  Modified aldrete scoring system
Discharge criteria Score
Activity: Able to move voluntarily or on command
   Four extremities 2
   Two extremities 1
   Zero extremities 0
Respiration
   Able to deep breathe and cough freely 2
   Dyspnea, shallow or limited breathing 1
   Apneic 0
Circulation
   Blood pressure ± 20 mmHg of preanesthetic level 2
   Blood pressure ± 20 - 50 mmHg preanesthetic level 1
   Blood pressure ± 50 mmHg of preanesthetic level 0
Consciousness
   Fully awake 2
   Arousable on calling 1
   Not responding 0
O2 saturation
   Able to maintain O2 saturation > 92% on room air 2
   Needs O2 inhalation to maintain O2 saturation > 90% 1
   O2 saturation < 90% even with O2 supplementation 0
Grade of gastric motility
No
   No or very weak gating movement of the pyloric ring is observed, but 
   the movement does not show strong contraction
   → No peristalsis
Mild
   A circular peristaltic wave is formed in the antrum but disappears 
   without reaching the pyloric ring, or circular contraction temporarily 
   occurs immediately before the pyloric ring
   → Peristaltic wave does not reach the pyloric ring
Moderate
   A pronounced peristaltic wave is formed and reaches the pyloric ring
   → Peristaltic wave reached the pyloric ring, which opens and closes, 
   showing star-like contraction as a result of the peristaltic wave
Vigorous
   Peristaltic wave is deep and pronounced and proceeds, strangulating 
   the antrum
   → Peristaltic wave reaches the pyloric ring, and the pyloric ring is 
   totally covered by the wave, the area exhibiting star-like contraction 
   protrudes toward the opening of the pyloric ring, and the mucosa is 
   pushed out from the central part of the opening
Kim N et al . Edation during endoscopic submucosal dissection
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Continuous and categorical variables were tested by 
using Student’s t test and χ 2 test (or Fisher’s exact 
test), respectively. Repeatedly measured variables 
such as SpO2, SBP, DBP, and HR were analyzed by a 
linear mixed model with patient indicator, group, time, 
and interaction between group and time as fixed effect 
factors. When the interaction between group and 
time was significant, post-hoc testing was performed 
with Bonferroni correction. All statistical tests were 
two­tailed at a significance level of 0.05. Statistical 
analyses were performed by using SPSS software (ver. 
19.0, SPSS Inc., Chicago, IL, United States) and PASS 
software (ver. 12, NCSS, LLC, Kaysville, Utah, United 
States).
The sample size of this study was referred from the 
previous randomized trial[18] comparing the safety and 
effectiveness between dexmedetomidine and propofol 
during oesophagus interventions.
RESULTS
No significant differences were observed in patient 
demographic data including age, sex ratio, height, 
weight, snoring history, and ASA classification (Table 4). 
Tumor characteristics, including histology, macroscopic 
appearance, location and size measured by the 
endoscopist were similar between the groups (Table 5).
Dexmedetomidine in the DR group and propofol 
in the PR group were infused at rates of 0.5 ± 0.3 
μg/kg per hour and 23.8 ± 16.5 μg/kg per minute, 
respectively. The infusion rates of remifentanil were 5.7 
± 1.4 μg/kg per hour and 6.3 ± 4.0 μg/kg per hour in 
the DR and PR groups, respectively (P = 0.451). Eight 
and 3 patients in the DR and PR groups, respectively, 
required propofol as a rescue sedative (P = 0.083) 
at 16.9 ± 10.3 mg and 13.3 ± 5.8 mg (P = 0.596), 
respectively (Table 6).
Complete resection was possible with 94.4% of the 
36 en bloc resections in the DR group and 100.0% of 
the 32 en bloc resections in the PR group. Moreover, 
Assessment of patient safety
Hemodynamic variables of SBP, DBP, HR, and SpO2 
were compared when measuring the MOAA/S score. 
All respiratory (apnea and oxygen desaturation) 
and hemodynamic (hypertension, hypotension, 
tachycardia, or bradycardia; defined as a change in 
baseline value of more than 20%) adverse events 
were recorded. Apnea was defined as not breathing 
spontaneously for at least 20 s. Oxygen desaturation 
was defined as SpO2 < 90%. We managed adverse 
respiratory events with a jaw thrust, mask ventilation, 
or by increasing oxygen flow. Ephedrine, nicardipine, 
atropine, or esmolol was administered for adverse 
hemodynamic events. The total amount of sedative 
drug and remifentanil were recorded.
Statistical analysis
The statistical methods of this study were reviewed 
by statisticians (Mi Kyung Song and Bo Gyoung Ma) 
from Biostatistics Collaboration Unit, Yonsei University 
College of Medicine, Seoul, South Korea. Data on 
baseline characteristics of study participants were 
presented as mean ± SD for continuous variables 
or frequency (percentage) for categorical variables. 
Table 4  Patient characteristics
DR group
(n  = 29)
PR group
(n  = 30)
P  value
Age (yr)     62.1 ± 10.3     62.9 ± 12.3 0.763
Male 19 (65.5) 22 (73.3) 0.514
Height (cm) 162.2 ± 7.7 164.8 ± 5.8 0.274
Weight (kg)   62.8 ± 8.5     65.1 ± 10.2 0.276
ASA classification n (%) 0.390
   Ⅰ 19 (65.5) 15 (50.0)
   Ⅱ   9 (31.0) 12 (40.0)
   Ⅲ 1 (3.4)   3 (10.0)
   Snoring history   9 (31.0)   7 (23.3) 0.506
Values are presented as the mean ± SD or frequency (percentage). DR 
group:  Indicates dexmedetomidine-remifentanil group; PR group: 
Propofol-remifentanil group; ASA: American society of anesthesiologists. 
Table 5  Tumor characteristics  n  (%)
DR group
(n  = 29) 
PR group
(n  = 30) 
P  value
Number of 
lesion
36 32
Histology Adenoma 19 (52.8) 17 (53.1) 0.995
Carcinoma 16 (44.4) 14 (43.8)
Others 1 (2.8) 1 (3.1)
Macroscopic 
appearance
Elevated 32 (88.9) 27 (84.4) 0.584
Flat or 
depressed
4 (11.1) 5 (15.6)
Location Upper body 3 (8.3) 3 (9.4) 0.945
Middle body 8 (22.2) 8 (25.0)
Lower body 25 (69.4) 21 (65.6)
Size (mm) 15.7 ± 7.0 14.0 ± 6.7 0.344
Values are presented as the mean ± SD or frequency (percentage).
Table 6  Drugs used for endoscopic submucosal dissection
DR group
(n  = 29)
PR group
(n  = 30)
P  value
Sedation duration (min) 42.8 ± 26.7 37.6 ± 18.5 0.477
Dexmedetomidine infusion rate 
(μg/kg per hour)
0.5 ± 0.3
Propofol infusion rate 
(μg/kg per minute)
23.8 ± 16.5
Remifentanil infusion rate 
(μg/kg per hour)
5.7 ± 1.4 6.3 ± 4.0 0.451
Additional propofol required
   Patients 8 (27.6) 3 (10.0) 0.083
   Dose (mg) 16.9 ± 10.3 13.3 ± 5.8 0.596
Butylscopolamine use
   Patients 4 (13.8) 10 (33.3) 0.078
   Dose (mg) 3.4 ± 9.3 10.0 ± 16.4 0.066
Values are presented as the mean ± SD or frequency (percentage).
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the duration of sedation was similar (P = 0.477).
Although the endoscope was more easily advanced 
through the throat in the PR group than in the DR 
group (P = 0.010), low­grade gastric motility (no or 
mild) was more frequent in the DR group (96.6% 
vs 73.3%, P = 0.013). Butylscopolamine was 
administered to 10 patients of the PR group compared 
with 4 patients of the DR group (P = 0.078). 
While the endoscopists were satisfied with the 
procedural performance and judged the procedures 
as favorable in all patients in the DR group and in only 
86.7% of patients in the PR group (P = 0.042), patient 
satisfaction was comparable between the two groups 
(Table 7). 
The Aldrete score at the end of the procedure was 
not different between the groups (9.5 ± 0.6 in the 
DR group and 9.4 ± 0.6 in the PR group, P = 0.924) 
and all patients left the PACU within 30 min (21.2 ± 
6.8 min in the DR group and 20.4 ± 5.8 min in the PR 
group, P = 0.636). 
No differences in the MOAA/S scale score, SBP, 
DBP, or SpO2 were observed. However, the mean 
change of HR over time was different between DR and 
PR groups (Figure 1). No cases of oxygen desaturation 
or any adverse hemodynamic events were observed 
during the ESD procedures in either group. 
DISCUSSION
We found that minimal sedation using dexmedeto­
midine­remifentanil could be substituted for propofol­
remifentanil during ESD, and that the endoscopists 
seemed to be satisfied with the procedural efficacy 
perhaps due to low gastric motility. 
This study has some clinical implications regarding 
the sedating protocol for ESD. First, our results 
suggest the importance of analgesics and optimal 
sedation level to avoid patient anxiety. ESD was 
safely performed under MOAA/S sedation levels of 
4­5 if adequate analgesic was provided. As shown 
in Figure 1, no patient needed management due to 
hemodynamic instability or adverse respiratory events 
despite the decreased HR in the DR group. We believe 
that continuous infusion of remifentanil enabled the 
patients to tolerate this procedure well in an orientated 
and anxiety­free state. The analgesic requirement 
for a painful procedure was evident in a previous 
colonoscopy trial, which was terminated early before 
enrolling the planned number of patients because 
of the higher rate of supplemental fentanyl required 
and adverse hemodynamic events in the group of 
patients administered dexmedetomidine alone[19]. 
International sedation guidelines for gastrointestinal 
110
100
90
80
70
60
50
T0     T1     T2     T3      T4      T5      T6     T7
Ra
te
/m
in
Figure 1  Changes of hemodynamic variables and SpO2 during endoscopic submucosal dissection. T0, just before the procedure; T1, 1 min after induction of 
sedation (1 min after a 5 min loading of dexmedetomidine in the DR group and 1 min after the propofol bolus injection in the PR group); T2, as the endoscope was 
passed into the esophagus; T3, as the endoscope marked the tumor region; T4, 5 min after epinephrine injection was given in the gastric submucosa; T5, at dissection 
of the gastric tumor region from the gastric submucosa; T6, once bleeding control was reached at the gastric bed; T7, and at the end of the procedure. HR: Heart rate; 
SpO2: Oxygen saturation; SBP: Systolic blood pressure; DBP: Diastolic blood pressure. 
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endoscopic procedures[20­22] recommend sedating 
patients to improve procedural performance. However, 
the adequate level of sedation for patients has 
not been well defined (conscious sedation vs deep 
sedation). Takimoto et al[11] compared the efficacy 
and safety of conscious sedation for ESD targeting a 
Ramsay sedation score (RSS) of 2­3 among propofol, 
dexmedetomidine, and midazolam. They found that 
dexmedetomidine provided comparable hemodynamic 
stability and improved oxygen saturation as well as no 
major surgical complications compared to propofol or 
midazolam. In comparison, two patients who received 
propofol or midazolam developed gastric perforation. 
An RSS of 2­3 represents a level of sedation that 
is similar to, but slightly deeper than, the MOAA/
S of 4-5 used in the present study (MOAA/S 4 = 
responding to normal verbal tone; RSS 3 = responding 
to commands). Sasaki et al[19] reported hypoxemia 
in 15.9%­17.8% of patients and hypotension in 
19.3%­34.4% of patients, suggesting a deeper 
sedation level and a higher rate of complications. In 
the present study, minimal sedation, regardless of 
the group, allowed the patients to achieve an Aldrete 
score of 9.5 at the end of the procedure and to leave 
the PACU within 30 min. Fast recovery may also be 
an economic benefit of minimal sedation. However, 
further pharmaco­economic evaluation between 
propofol and dexmedetomidine will not be discussed 
here because of the costal differences of medications 
among countries.
Second, regarding procedural performance, 
the endoscopists felt that the endoscope could be 
more easily advanced into the throat with propofol 
(endoscopists reported the insertion “very easy” 
in 7 of 29 patients in the DR group vs 17 of 30 
patients in the PR group, P = 0.01). The underlying 
causes of this difference are unclear but might be 
explained, in part, by the different effect of propofol 
and dexmedetomidine on the pharyngeal function. 
Kiriyama et al[23] assessed the effects of a bolus of 0.5 
mg/kg propofol injected before ESD compared to no 
bolus of propofol and found that the propofol bolus 
decreased pharyngeal muscle tone and obtunded the 
scope-stimulated pharyngeal reflex in 77% of patients 
compared to 21% of patients with no bolus. Therefore, 
in the present study, the intact pharyngeal function in 
the DR group may have made it more difficult for the 
endoscopists to advance the scope into the throat. 
Inhibiting gastric motility is crucial for successful 
performance of ESD, and this is the first report of 
endoscopist evaluated gastric motility during ESD in 
relation to two different sedation protocols (Table 7). 
The endoscopists graded gastric motility as low (no 
and mild among four grades) in 96.6% of the DR 
group and in 73.3% of the PR group (P = 0.013). 
Corroborating the report of lower gastric motility by 
the endoscopists, patients in the DR group required 
butylscopolamine less frequently to suppress gastric 
motility than those in the PR group. The effects of 
dexmedetomidine on gastric motility seemed to differ 
according to subject and dosage. In a previous study, 
infusion with a 1.0 μg/kg loading dose for 20 min 
followed by infusion of 0.7 μg/kg per hour inhibited 
gastric emptying in healthy volunteers, as measured 
by paracetamol absorption compared to 0.1 mg/kg 
morphine or placebo[12]. In contrast, Memiş et al[24] 
found no difference in gastric emptying time between 
propofol (2 mg/kg per hour) and dexmedetomidine 
(0.2 μg/kg per hour) for 5 h in critically ill patients. 
This discrepancy may have resulted from the different 
doses of drugs and measuring methods (direct 
visualization vs indirect paracetamol absorption test) 
used in the two studies. Dexmedetomidine itself 
does not alter gastric motility in rats but markedly 
enhances the inhibitory effect of morphine on gastric 
motility[25]. We are uncertain of the interactive effect of 
dexmedetomidine and remifentanil on gastric motility. 
We believed that both sedation protocols were effective 
for ESD considering that the endoscopists were able 
to perform complete resection at a comparable rate 
between the two groups (94.4% vs 100%).
However, our study had some limitations. We 
analyzed a small number of patients, which limited 
the statistical power of our results. If we carry out the 
follow­up study, 143 subjects will be needed for each 
group to keep the statistical power of 80%. Gastric 
motility did not differ between the two groups (P = 
0.101) when measured using the four grades (no, 
Table 7  Efficacy of procedural performance 
DR group
(n  = 29)
PR group
(n  = 30)
P  value
Advancing scope into throat 0.010
   Very easy   7 (24.1) 17 (56.7)
   Easy 14 (48.3) 12 (40.0)
   Slight difficult 1 (3.4) 1 (3.3)
   Difficult   7 (24.1) 0 (0.0)
Gastric motility 0.101
   No 21 (72.4) 16 (53.3)
   Mild   7 (24.1)   6 (20.0)
   Moderate 1 (3.4)   7 (23.3)
   Vigorous 0 (0.0) 1 (3.3)
   Low: No + mild 28 (96.6) 22 (73.3) 0.013
   High: Moderate + vigorous 1 (3.4)   8 (26.7)
Endoscopist’s satisfaction 0.216
   Very good 21 (72.4) 17 (56.7)
   Good   8 (27.6)   9 (30.0)
   Fair 0 (0.0) 2 (6.7)
   Bad 0 (0.0) 2 (6.7)
   Favorable: Very good + good   29 (100.0) 26 (86.7) 0.042
   Unfavorable: Fair + bad 0 (0.0)   4 (13.3)
Patients’ satisfaction of sedation 0.616
   Very good   4 (13.8)   7 (23.3)
   Good 21 (72.4) 20 (66.7)
   Bearable   4 (13.8)   3 (10.0)
   Unbearable 0 (0.0) 0 (0.0)
Values are presented as frequency (percentage). The gastric motility and 
endoscopists’ satisfaction were reclassified as low (no + mild) or high 
(moderate + vigorous) and favorable (very good + good) or unfavorable 
(fair + bad), respectively. 
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mild, moderate, and vigorous); however, there was 
a significant difference when just two grades of low 
(no/mild) and high (moderate/vigorous) were applied 
(P = 0.013). This same issue was also observed with 
the statistical analysis of endoscopists’ satisfaction. 
We did not find any significant difference when the 
ratings were based on four grades (very good, good, 
fair, and bad). However, when satisfaction was divided 
into favorable (very good/good) and unfavorable 
(fair/bad), the endoscopists were in favor of the 
dexmedetomidine­remifentanil treatment (favorable, 
100% in the DR group vs 86.7% in the PR group, P 
= 0.042). Although there were no serious adverse 
respiratory events during ESD in both groups, we could 
not exclude the possibility of hypercapnia because 
we did not measure the partial pressure of carbon 
dioxide (PaCO2) through arterial blood gas analysis. 
To blind endoscopists from the type of anesthesia, we 
covered the patients’ venous access sites with a drape; 
however, we are unsure whether endoscopists were 
able to correctly identify the type of sedative drugs 
from the difference in the pharmacologic properties 
between dexmedetomidine and propofol. Therefore, 
we could not completely eliminate the bias of personal 
preference when they answered the questionnaires. 
Finally, our study design did not include a psychometric 
test for patients or comprehensive questionnaires 
to assess patients and endoscopists satisfaction as 
suggested by Vargo et al[26]. 
In conclusion, use of dexmedetomidine and 
remifentanil targeting minimal sedation could be 
substituted for propofol­remifentanil sedation during 
ESD procedure. However, the effect of suppressing 
gastric motility with dexmedetomidine­remifentanil 
sedation needs further studies with a greater number 
of subjects. 
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Background
Endoscopic submucosal dissection (ESD) is accompanied with greater and 
longer patient discomfort and pain than conventional endoscopic procedures. 
Therefore, a combination regimen with a sedative and an analgesic, such as 
propofol and remifentanil, is recommended. However, propofol depresses 
respiratory function in a dose-dependent manner and aspiration pneumonia 
can occur. Dexmedetomidine, another sedative agent with lack of respiratory 
depression, suppresses gastrointestinal motility and may improve the chances 
for successful ESD. Thus, we compared the procedural efficacy and patient 
safety of dexmedetomidine-remifentanil to propofol-remifentanil during ESD.
Research frontiers
Aspiration pneumonia occurs with an incidence of 2.3% following ESD under 
sedation with propofol perhaps due to dose-dependent respiratory depression. 
Dexmedetomidine, a selective α2-adrenoceptor agonist with sedative and 
analgesic effects that preserves ventilator function, has been successfully used 
during colonoscopy. In addition, dexmedetomidine suppresses gastrointestinal 
motility in healthy volunteers whereas propofol does not.
Innovations and breakthroughs
The sedation level was maintained at MOAA/S of 4-5 with either sedating 
regimen (propofol-remifentanil or dexmedetomidine-remifentanil). What we 
found in this study were as follows. The patients tolerated the ESD procedure 
well and safely under minimal sedation under either sedating regimen with 
pain adequately controlled. However, the endoscopists favored the regimen 
of dexmedetomidine-remifentanil perhaps due to the suppression of gastric 
motility.
Applications
Because the endoscopic procedure can vary greatly among patients in regard 
to anxiety, pain, and duration, it is important to regard sedation and analgesia 
separately to avoid over-sedation. Dexmedetomidine may provide benefits to 
the sedation regimen during ESD because it has sedative effects, analgesic 
effects, the ability to suppress gastric mobility and, more importantly, the ability 
to preserve respiratory drive.
Terminology
The endoscopic submucosal dissection procedure lasts for hours and is 
accompanied by pain. Propofol and dexmedetomidine are commonly used 
sedative agents that work through GABAA receptor and a selective α2-
adrenoceptor, respectively. Remifentanil is a synthetic opioid with rapid onset 
and offset of action. 
Peer-review
The authors compared the efficacy and safety of sedation between 
dexmedetomidine-remifentanil and propofol-remifentanil for use during 
ESD. Fifty-nine patients scheduled for ESD were randomly assigned to a 
dexmedetomidine-remifentanil group or a propofol-remifentanil group. The 
efficacy and safety of dexmedetomidine and remifentanil were comparable 
to propofol and remifentanil during ESD. The endoscopists favored 
dexmedetomidine mainly due to lower gastric motility. 
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